Suraksha Diagnostics Q2 FY27 Results: Revenue Up 26.4%, PAT Soars 69%
Suraksha Diagnostics reported a strong Q2 FY27 with revenue up 26.4% to ₹100.57 crore and PAT soaring 69% to ₹14.95 crore. The company commissioned five new centers, entering Jharkhand. Mature centers achieved 42% EBITDA margin. Management expects the INR 100 crore quarterly revenue run rate to continue from Q4 FY27 and aims for 100 centers by FY28.
The strong financial performance, including substantial revenue and profit growth, coupled with network expansion into new states and a positive outlook for continued growth, indicates a high impact on investor confidence and market perception.
The company reported significant year-on-year growth in revenue (26.4%) and PAT (69%) for Q2 FY27, along with improved EBITDA margins. The expansion into new geographies and positive outlook for future performance contribute to a positive sentiment.
Suraksha Diagnostic Limited announced strong financial results for the second quarter and half-year ended September 30, 2026. The company reported a total income of ₹100.57 crore for Q2 FY27, a significant 26.4% increase year-on-year from ₹79.58 crore in Q2 FY26. EBITDA for the quarter stood at ₹36.32 crore, up from ₹24.97 crore in the previous year, with an improved EBITDA margin of 36.7% compared to 31.7%. Profit After Tax (PAT) surged by 69% to ₹14.95 crore from ₹8.83 crore in Q2 FY26, achieving a PAT margin of 15.1%.
For the half-year ended September 30, 2026, total income reached ₹189.31 crore, a 23.7% growth from ₹153.07 crore in H1 FY26. EBITDA for the half-year was ₹67.85 crore, up from ₹49.62 crore, with an EBITDA margin of 36.3%. PAT for H1 FY27 was ₹27.80 crore, a 54% increase from ₹18.00 crore in H1 FY26, with a PAT margin of 14.9%.
The company commissioned five new centers during the quarter, marking its entry into Jharkhand. Mature centers achieved a 42% EBITDA margin, and centers operational for less than two years improved their EBITDA margin to 11.8%. The company expects steady-state margins to be around 34% to 35% next year. Genomics is seen as a promising area for future growth. Home sample collections currently contribute around 10% of revenues.
During the earnings call, management confirmed that while Q3 revenue might see a seasonal dip, the INR 100 crore quarterly run rate is expected to be maintained from Q4 onwards. The company aims to reach 100 centers by the end of FY28. Concerns about margin pressure due to expansion were addressed, with management stating that maturing centers balance out the costs of new ones.
What to do with a filing like this
Suraksha Diagnostic Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Suraksha Diagnostic Limited. Read the original for the full detail.